Stay updated on ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial
Sign up to get notified when there's something new on the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page.

Latest updates to the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page
- CheckyesterdayChange Detected- Revision badge updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedAdded Revision: v3.4.2. Removed the prior funding/operating-status notice (Revision: v3.4.1).SummaryDifference0.3%

- Check36 days agoChange DetectedAdded a government funding/status notice about the NIH Clinical Center and operations. Updated the site version from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check43 days agoChange DetectedAdded a glossary toggle and new labels (Last Update Submitted that Met QC Criteria; Revision: v3.4.0) while removing older labels with different capitalization/wording (Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4).SummaryDifference0.1%

- Check58 days agoChange DetectedThe revision line has been updated to v3.3.4, replacing the previous v3.3.3.SummaryDifference0.0%

- Check79 days agoChange DetectedNew study sites were added across Belgium, Canada, Czechia, Hungary, Poland, Spain, and other regions. Several previously listed locations were removed, and the page revision updated to v3.3.3.SummaryDifference1%

Stay in the know with updates to ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page.